1. Home
  2. WVE vs PCN Comparison

WVE vs PCN Comparison

Compare WVE & PCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • PCN
  • Stock Information
  • Founded
  • WVE 2012
  • PCN 2001
  • Country
  • WVE Singapore
  • PCN United States
  • Employees
  • WVE N/A
  • PCN N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • PCN Investment Managers
  • Sector
  • WVE Health Care
  • PCN Finance
  • Exchange
  • WVE Nasdaq
  • PCN Nasdaq
  • Market Cap
  • WVE 915.6M
  • PCN 810.6M
  • IPO Year
  • WVE 2015
  • PCN N/A
  • Fundamental
  • Price
  • WVE $7.22
  • PCN $12.70
  • Analyst Decision
  • WVE Strong Buy
  • PCN
  • Analyst Count
  • WVE 11
  • PCN 0
  • Target Price
  • WVE $20.91
  • PCN N/A
  • AVG Volume (30 Days)
  • WVE 1.1M
  • PCN 218.7K
  • Earning Date
  • WVE 05-08-2025
  • PCN 01-01-0001
  • Dividend Yield
  • WVE N/A
  • PCN 9.73%
  • EPS Growth
  • WVE N/A
  • PCN N/A
  • EPS
  • WVE N/A
  • PCN N/A
  • Revenue
  • WVE $104,939,000.00
  • PCN N/A
  • Revenue This Year
  • WVE N/A
  • PCN N/A
  • Revenue Next Year
  • WVE N/A
  • PCN N/A
  • P/E Ratio
  • WVE N/A
  • PCN N/A
  • Revenue Growth
  • WVE N/A
  • PCN N/A
  • 52 Week Low
  • WVE $4.25
  • PCN $10.70
  • 52 Week High
  • WVE $16.74
  • PCN $14.48
  • Technical
  • Relative Strength Index (RSI)
  • WVE 61.17
  • PCN 45.19
  • Support Level
  • WVE $5.98
  • PCN $12.65
  • Resistance Level
  • WVE $6.30
  • PCN $12.77
  • Average True Range (ATR)
  • WVE 0.33
  • PCN 0.10
  • MACD
  • WVE 0.14
  • PCN 0.01
  • Stochastic Oscillator
  • WVE 92.21
  • PCN 50.00

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About PCN Pimco Corporate & Income Strategy Fund

PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.

Share on Social Networks: